USPTO Examiner DEAK LESLIE R - Art Unit 3799

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19303491SYSTEMS AND METHODS FOR REMOVING UNDESIRABLE MATERIAL WITHIN A CIRCULATORY SYSTEM DURING A SURGICAL PROCEDUREAugust 2025March 2026Allow610NoNo
19254202SYSTEMS AND METHODS FOR REMOVING UNDESIRABLE MATERIAL WITHIN A CIRCULATORY SYSTEMJune 2025November 2025Allow410YesNo
19190443Endothelial-Integrated Stent for Schlemm's Canal and Controlled Aqueous Humor OutflowApril 2025June 2025Allow200YesNo
19077384SYSTEM AND METHOD FOR COLLECTING PLASMAMarch 2025May 2025Allow310YesNo
19043018IMPLANTABLE BIOLOGIC STENT AND SYSTEM FOR BIOLOGIC MATERIAL SHAPING AND PREPARATION IN THE TREATMENT OF GLAUCOMAJanuary 2025December 2025Allow1120YesNo
18871508PERFORATING DEVICEDecember 2024March 2025Allow400YesNo
18955269SYSTEM AND METHOD FOR COLLECTING PLASMANovember 2024March 2025Allow410NoNo
18936174APPARATUS FOR DRAWING MEDICINE FROM A MEDICINE CONTAINER TO A SYRINGENovember 2024January 2025Allow300NoNo
18792233METHODS AND SYSTEMS FOR TRANSCAVAL TREATMENT OF ANEURYSMSAugust 2024January 2025Allow611YesNo
18772936SHUNT AND METHOD FOR TREATING GLAUCOMAJuly 2024August 2025Allow1300NoNo
18747453BLOOD-GAS EXCHANGE DEVICE AND METHODS OF USEJune 2024September 2024Allow300NoNo
18672118SYSTEMS AND METHODS FOR REMOVING UNDESIRABLE MATERIAL WITHIN A CIRCULATORY SYSTEMMay 2024December 2024Allow710NoNo
18641626SYSTEMS AND METHODS FOR REMOVING UNDESIRABLE MATERIAL WITHIN A CIRCULATORY SYSTEMApril 2024September 2024Allow410NoNo
18634734METHODS AND SYSTEMS FOR TRANSCAVAL TREATMENT OF ANEURYSMSApril 2024January 2025Allow911YesNo
18627596MULTI-VIAL ADAPTERS FOR RECONSTITUTING OR DILUTING LYOPHILIZED OR CONCENTRATED DRUG PRODUCTSApril 2024December 2024Allow820YesNo
18623033INTEGRATED URINE ANAEROBIC COLLECTION AND CULTURE APPARATUSApril 2024August 2024Allow400NoNo
18419262METHODS AND SYSTEMS FOR TRANSCAVAL TREATMENT OF ANEURYSMSJanuary 2024July 2024Allow501YesNo
18407218DEVICES FOR BLOOD CAPTURE AND REINTRODUCTION DURING ASPIRATION PROCEDUREJanuary 2024August 2024Allow710NoNo
18520633Electric nasal aspirator with anti-blocking and cleaning functionsNovember 2023January 2026Allow2500NoNo
18559843APPLICATION CONTAINERNovember 2023February 2026Allow2800NoNo
18380909ONCODIALYSIS SYSTEM AND METHOD FOR PERSONALIZED AUTOLOGOUS CANCER VACCINE AND BLOOD PURIFICATIONOctober 2023August 2024Allow1020YesNo
18473203EYE STENTS AND DELIVERY SYSTEMSSeptember 2023April 2024Allow610YesNo
18348295ADJUSTABLE FLOW GLAUCOMA SHUNTS HAVING NON-LINEARLY ARRANGED FLOW CONTROL ELEMENTS, AND ASSOCIATED SYSTEMS AND METHODSJuly 2023July 2025Allow2500YesNo
18342447Dialysis Sheath For Use In Accessing A Dialysis Arteriovenous Graft Or Fistula And Methods Of UseJune 2023January 2024Allow710YesNo
18336265FLEXIBLE SHUNT IMPLANTSJune 2023October 2025Allow2810NoNo
18254741SECURE RECONSTRUCTION DEVICEMay 2023November 2023Allow500NoNo
18310761SHUNTING SYSTEMS WITH ROTATION-BASED FLOW CONTROL ASSEMBLIES, AND ASSOCIATED SYSTEMS AND METHODSMay 2023March 2026Allow3401NoNo
18129866ONCODIALYSIS SYSTEM AND METHOD FOR PERSONALIZED CANCER VACCINE AND BLOOD PURIFICATIONApril 2023April 2024Allow1321YesNo
18185249INTRAOCULAR SHUNTS WITH LOW-PROFILE ACTUATION ELEMENTS AND ASSOCIATED SYSTEMS AND METHODSMarch 2023March 2026Allow3610YesNo
18182115SYSTEM AND METHOD FOR CONTROLLING OXYGEN-ENRICHMENT THERAPY BASED ON MICROVASCULAR RESISTANCE FEEDBACKMarch 2023February 2026Allow3510NoNo
18043941STENT IMPLANT FOR TREATING GLAUCOMA BY MEANS OF INTRAOCULAR FLUID DRAINAGE FROM THE ANTERIOR CHAMBERMarch 2023February 2026Allow3610YesNo
18022364UNIVERSAL HOLDER SYSTEMFebruary 2023October 2025Allow3101YesNo
18171651URETERAL STENT ASSEMBLY AND STENT PUSHER THEREOFFebruary 2023June 2025Allow2700YesNo
18171639EXTRACORPOREAL BLOOD FILTERING MACHINE AND METHODSFebruary 2023February 2024Abandon1210NoNo
18165664SELF-SEALING TRABECULECTOMYFebruary 2023May 2025Allow2700NoNo
18018826FILTER SYSTEM FOR A CLOSED FLUID-TRANSFER SYSTEM WITH PRESSURE EQUALIZATIONJanuary 2023May 2025Allow2700YesNo
18159438Devices And Methods For Advancing A WireJanuary 2023September 2025Allow3200NoNo
18006505METHOD FOR CHECKING THE FUNCTIONALITY OF CONVEYING DEVICES OF A MEDICAL TREATMENT APPARATUS, AND APPARATUSESJanuary 2023September 2025Allow3110YesNo
18156211SYSTEM AND METHODS FOR REMOVING UNDESIRABLE MATERIAL WITHIN A CIRCULATORY SYSTEM DURING A SURGICAL PROCEDUREJanuary 2023September 2025Allow3200YesNo
18153293GLAUCOMA STENT AND METHODS THEREOF FOR GLAUCOMA TREATMENTJanuary 2023December 2025Allow3510NoNo
18151816IMPLANTS WITH CONTROLLED DRUG DELIVERY FEATURES AND METHODS OF USING SAMEJanuary 2023December 2025Allow3510YesNo
18014772BLOOD PURIFICATION APPARATUSJanuary 2023July 2025Allow3110NoNo
18092235FLUID TRANSFER COUPLINGSDecember 2022December 2023Allow1212NoNo
18013117AQUEOUS HUMOR DRAINAGE DEVICE WITH ADJUSTABLE TUBE DIAMETERDecember 2022February 2026Allow3720YesNo
18008630A SHUNT AND METHOD FOR TREATING GLAUCOMADecember 2022August 2025Allow3210NoNo
18000671EYE SHUNT SYSTEM AND METHODSDecember 2022August 2025Allow3210NoNo
17979631ADJUSTABLE FLOW GLAUCOMA SHUNTS AND ASSOCIATED SYSTEMS AND METHODSNovember 2022July 2025Allow3300YesNo
17979664ADJUSTABLE FLOW GLAUCOMA SHUNTS AND ASSOCIATED SYSTEMS AND METHODSNovember 2022July 2025Allow3300YesNo
17937632SELECTIVE CYTOPHERESIS DEVICES AND RELATED METHODS THEREOFOctober 2022October 2025Abandon3610NoNo
17914399SURGICAL METHOD, DEVICE, SYSTEM AND KIT FOR THE TREATMENT OF HYDROCEPHALUSSeptember 2022May 2025Allow3201YesNo
17933593PERFUSION DOSAGE FORMSeptember 2022April 2023Allow720NoNo
17948691SYSTEM AND METHOD FOR REDUCING GASEOUS MICROEMBOLI USING VENOUS BLOOD BYPASS WITH FILTERSeptember 2022February 2026Allow4010NoNo
17911871ULTRAFILTRATION CONTROL IN EXTRACORPOREAL BLOOD PROCESSINGSeptember 2022January 2026Allow4020NoNo
17943410SYSTEM AND METHOD FOR COLLECTING PLASMASeptember 2022April 2023Allow710NoNo
17899434EXTRACORPOREAL CIRCULATORAugust 2022February 2026Abandon4110NoNo
17822716IMPLANTS WITH CONTROLLED DRUG DELIVERY FEATURES AND METHODS OF USING SAMEAugust 2022August 2025Allow3610YesNo
17802254INTRAOCULAR SHUNTS WITH LOW-PROFILE ACTUATION ELEMENTS AND ASSOCIATED SYSTEMS AND METHODSAugust 2022March 2023Allow600NoNo
17895341COMBINED BLOOD PUMP AND OXYGENATOR SYSTEM AND RELATED METHODSAugust 2022June 2025Allow3400NoNo
17814542CASSETTE APPARATUS UTILIZING ELECTRIC FIELD FOR PROCESSING OF BLOOD TO NEUTRALIZE PATHOGEN CELLS THEREINJuly 2022August 2023Allow1300NoNo
17814549CASSETTE APPARATUS UTILIZING VENTING FOR PROCESSING OF BLOOD TO REMOVE PATHOGEN CELLS THEREINJuly 2022September 2023Allow1400NoNo
17793799METHOD AND DEVICES FOR DETERMINING A TIME POINT FOR MEASURING PRESSURE MEASUREMENTSJuly 2022November 2025Allow4020YesNo
17866429INTRAOCULAR IMPLANTS AND METHODS AND KITS THEREFORJuly 2022December 2025Allow4110NoNo
17838066Method and Apparatus for Implant in the Conventional Aqueous Humor Outflow Pathway of a Mammalian EyeJune 2022April 2023Allow1010YesNo
17834031DEVICE AND METHOD FOR PERFUSING A SUBJECT'S HEART VIA THE CORONARY SINUSJune 2022February 2023Allow920YesNo
17826331SYSTEMS AND METHODS FOR TREATMENT OF FLUID OVERLOADMay 2022October 2025Allow4120NoNo
17826326SYSTEMS AND METHODS FOR TREATMENT OF FLUID OVERLOADMay 2022July 2025Allow3810NoNo
17824789CURVED MICROTUBE FOR TREATING GLAUCOMAMay 2022June 2025Allow3710YesNo
17737823SYSTEMS, DEVICES, AND METHODS FOR FLUID MONITORINGMay 2022August 2025Allow4010NoNo
17765590ADJUSTABLE FLOW GLAUCOMA SHUNTS AND ASSOCIATED SYSTEMS AND METHODSMarch 2022October 2022Allow600NoNo
17763163Medical Devices and Methods Thereof for Determining Bacterial Infections in BloodMarch 2022December 2022Allow901NoNo
17701378Implantable Shunt System and MethodMarch 2022June 2025Allow3910NoNo
17684544SHUNTING SYSTEMS WITH ROTATION-BASED FLOW CONTROL ASSEMBLIES, AND ASSOCIATED SYSTEMS AND METHODSMarch 2022April 2025Allow3700YesNo
17651636CONTROLLED DRUG DELIVERY OCULAR IMPLANTS AND METHODS OF USING SAMEFebruary 2022June 2025Allow3910YesNo
17675044PURGER DEVICE FOR OXYGENATORSFebruary 2022March 2025Allow3600NoNo
17669883Methods of Amelioration of Cerebrospinal Fluid and Devices and Systems ThereforFebruary 2022March 2025Allow3711NoNo
17589454System for Washing Red Blood Cells to Reduce HemolysisJanuary 2022December 2024Allow3411YesNo
17625410TREATMENT SYSTEMS WITH ADJUSTABLE FLOW SHUNTS AND SENSORS, AND ASSOCIATED DEVICES AND METHODSJanuary 2022September 2025Abandon4410NoNo
17569329EYE STENTS AND DELIVERY SYSTEMSJanuary 2022April 2025Allow3910NoNo
17558621IMPLANTABLE RENAL REPLACEMENT THERAPY DEVICEDecember 2021August 2025Allow4421NoNo
17610426Method and Apparatus for Implant in the Conventional Aqueous Humor Outflow Pathway of a Mammalian EyeNovember 2021December 2025Allow4930YesNo
17606661ADJUSTABLE FLOW GLAUCOMA SHUNTS AND ASSOCIATED SYSTEMS AND METHODSOctober 2021August 2022Allow1010YesNo
17506565ADJUSTABLE SHUNTS AND ASSOCIATED SYSTEMS AND METHODSOctober 2021March 2025Allow4110NoNo
17500224ADJUSTABLE FLOW GLAUCOMA SHUNTS AND METHODS FOR MAKING AND USING SAMEOctober 2021November 2024Allow3700NoNo
17500210ADJUSTABLE FLOW GLAUCOMA SHUNTS AND METHODS FOR MAKING AND USING SAMEOctober 2021November 2024Allow3700NoNo
17498422BLOOD CIRCULATION SYSTEMOctober 2021February 2025Allow4010NoNo
17444960METHOD FOR CONTROLLING PLACEMENT OF INTRAOCULAR IMPLANTSAugust 2021October 2024Allow3800NoNo
17428561PLATELET LYSATE PRODUCTION METHOD, PRODUCTION SYSTEM, AND BAG SETAugust 2021April 2025Allow4421YesNo
17427155LIQUID TRANSFER DEVICEJuly 2021May 2022Allow1010NoNo
17388796DEVICES FOR ACCESSING MEDICINAL FLUID FROM A CONTAINERJuly 2021March 2025Allow4310NoNo
17369127METHOD FOR EXTRACORPOREAL BLOOD PURIFICATION AND DIALYSATE DISPOSALJuly 2021January 2025Allow4310NoNo
17353787NEW STANDARDIZATIONS & MEDICAL DEVICES FOR THE PREPARATION OF PLATELET RICH PLASMA (PRP) OR BONE MARROW CONCENTRATE (BMC) ALONE OR IN COMBINATION WITH HYALURONIC ACIDJune 2021August 2025Allow5030YesNo
17345544METHODS AND SYSTEMS FOR ESTABLISHING RETROGRADE CAROTID ARTERIAL BLOOD FLOWJune 2021July 2024Allow3700NoNo
17303857IMPLANTS WITH CONTROLLED DRUG DELIVERY FEATURES AND METHODS OF USING SAMEJune 2021September 2024Allow3910NoNo
17339103METHOD AND SYSTEMS FOR CLEARING BLOOD OF ACTIVE PATHOGENSJune 2021December 2025Abandon5421NoNo
17299055Implantable Shunt System and MethodJune 2021February 2022Allow910NoNo
17317455DEVICES AND METHODS FOR NEEDLELESS AND NEEDLED EXTRACTION OF CONTENTS FROM VIALSMay 2021September 2024Allow4110NoNo
17291771Ureteral Catheter StructureMay 2021August 2024Allow4000NoNo
17242464IMPLANTABLE RENAL REPLACEMENT THERAPY DEVICEApril 2021August 2021Allow410NoNo
17239609METHOD AND SYSTEM FOR CONTROLLED HYPERTHERMIAApril 2021November 2021Allow700NoNo
17237911METHODS AND SYSTEMS FOR ESTABLISHING RETROGRADE CAROTID ARTERIAL BLOOD FLOWApril 2021September 2024Allow4110NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DEAK, LESLIE R.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
11
Examiner Affirmed
8
(72.7%)
Examiner Reversed
3
(27.3%)
Reversal Percentile
43.5%
Lower than average

What This Means

With a 27.3% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
27
Allowed After Appeal Filing
6
(22.2%)
Not Allowed After Appeal Filing
21
(77.8%)
Filing Benefit Percentile
30.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 22.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner DEAK, LESLIE R - Prosecution Strategy Guide

Executive Summary

Examiner DEAK, LESLIE R works in Art Unit 3799 and has examined 313 patent applications in our dataset. With an allowance rate of 86.3%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 40 months.

Allowance Patterns

Examiner DEAK, LESLIE R's allowance rate of 86.3% places them in the 64% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.

Office Action Patterns

On average, applications examined by DEAK, LESLIE R receive 1.80 office actions before reaching final disposition. This places the examiner in the 40% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by DEAK, LESLIE R is 40 months. This places the examiner in the 25% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +7.2% benefit to allowance rate for applications examined by DEAK, LESLIE R. This interview benefit is in the 36% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 32.4% of applications are subsequently allowed. This success rate is in the 68% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 39.2% of cases where such amendments are filed. This entry rate is in the 60% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 36.4% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 35% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 62.1% of appeals filed. This is in the 40% percentile among all examiners. Of these withdrawals, 38.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 39.7% are granted (fully or in part). This grant rate is in the 29% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 4.5% of allowed cases (in the 84% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 51% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.